STOCK TITAN

[Form 4] Vor Biopharma Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Vor Biopharma (VOR) reported insider sales on a Form 4 by Reprogrammed Interchange LLC, attributed to director Reid Hoffman. The transactions occurred on October 1–3, 2025 and were executed in multiple trades at weighted-average prices within a disclosed range of $36.82 to $42.70. Following the reported sales, the filing shows 1,597,308 shares beneficially owned, held directly. The share figures reflect a 1-for-20 reverse stock split effected on September 18, 2025. The filing notes Hoffman may be deemed a beneficial owner through shared control of Reprogrammed and disclaims ownership except to his pecuniary interest.

Positive

  • None.

Negative

  • None.

Insights

Routine Form 4 detailing multi-day insider sales with post‑trade holdings.

The filing records sales by Reprogrammed Interchange LLC, with attribution to director Reid Hoffman. Prices are reported as weighted averages for trades executed across price ranges, which is typical when multiple fills occur the same day. The remaining beneficial ownership shown is 1,597,308 shares after the listed transactions.

The share counts reflect a 1-for-20 reverse stock split effective September 18, 2025, ensuring comparability of amounts. Ownership is reported as direct, with a standard disclaimer that Hoffman may be deemed a beneficial owner through shared control and indirect pecuniary interest in Reprogrammed.

These disclosures are administrative and do not specify proceeds use or strategic changes. Actual impact on float or trading depends on market absorption and holder activity disclosed in subsequent filings, if any.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Reprogrammed Interchange LLC

(Last) (First) (Middle)
101 MISSION STREET, SUITE 1000

(Street)
SAN FRANCISCO CA 94105

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Vor Biopharma Inc. [ VOR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/01/2025 S 1,400 D $39.1925(1) 1,637,660(2)(3) D
Common Stock 10/02/2025 S 4,937 D $37.2057(4) 1,632,723(3) D
Common Stock 10/02/2025 S 1,513 D $38.3771(5) 1,631,210(3) D
Common Stock 10/02/2025 S 7,700 D $39.5728(6) 1,623,510(3) D
Common Stock 10/02/2025 S 13,001 D $40.1282(7) 1,610,509(3) D
Common Stock 10/02/2025 S 5,300 D $42.319(8) 1,605,209(3) D
Common Stock 10/03/2025 S 3,200 D $37.3731(9) 1,602,009(3) D
Common Stock 10/03/2025 S 4,701 D $38.1444(10) 1,597,308(3) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
Reprogrammed Interchange LLC

(Last) (First) (Middle)
101 MISSION STREET, SUITE 1000

(Street)
SAN FRANCISCO CA 94105

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Hoffman Reid

(Last) (First) (Middle)
101 MISSION STREET, SUITE 1000

(Street)
SAN FRANCISCO CA 94105

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. This transaction was executed in multiple trades at prices ranging from $39.11 to $39.415. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
2. The number of shares beneficially owned reflects the 1-for-20 reverse stock split effected September 18, 2025.
3. The securities are held by Reprogrammed Interchange LLC ("Reprogrammed"). Reid Hoffman may be deemed a beneficial owner of securities held by Reprogrammed by virtue of his shared control over and indirect pecuniary interest in Reprogrammed. Mr. Hoffman disclaims beneficial ownership of the securities held by Reprogrammed, except to the extent of his pecuniary interest therein.
4. This transaction was executed in multiple trades at prices ranging from $36.82 to $37.60. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
5. This transaction was executed in multiple trades at prices ranging from $37.85 to $38.57. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
6. This transaction was executed in multiple trades at prices ranging from $39.20 to $39.84. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
7. This transaction was executed in multiple trades at prices ranging from $39.86 to $40.70. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
8. This transaction was executed in multiple trades at prices ranging from $42.00 to $42.70. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
9. This transaction was executed in multiple trades at prices ranging from $36.88 to $37.69. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
10. This transaction was executed in multiple trades at prices ranging from $38.00 to $38.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
/s/ Reid Hoffman 10/03/2025
/s/ Frank Huang, Manager of Reprogrammed Interchange LLC 10/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Vor Biopharma Inc.

NASDAQ:VOR

VOR Rankings

VOR Latest News

VOR Latest SEC Filings

VOR Stock Data

274.54M
37.51M
39.09%
43.63%
15.62%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
BOSTON